Disclosure
Affiliate and Referral Disclosure
Released: · Last reviewed:
Tirzepatide Editorial is affiliate-supported and may earn a commission when readers enroll through links on this site. That is stated once, in a general disclosure in the footer of every page. The only commercial relationship the publisher has disclosed is an affiliate/referral relationship with NexLife, disclosed September 4, 2026; NexLife is also the site's #1 editorial pick (94/100 under methodology v4.1). Outbound provider links carry rel="nofollow noopener" and UTM parameters, and the price a reader pays is the provider's own published price.
Key takeaways
- One general disclosure, in the footer of every page, covers the whole site: “Tirzepatide Editorial is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report.”
- The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04), recorded on the ownership page and in the public provider dataset.
- Outbound provider links carry
rel="nofollow noopener"and UTM parameters naming this site and the page; no link is marked sponsored, and pages no longer carry separate relationship boxes. - NexLife is the site's #1 editorial pick, scored 94/100 under methodology v4.1. It is not the lowest price on file, and price tables stay sorted by price.
- A dismissible bar headed “NexLife, our #1 pick” appears at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages.
| Disclosure model | One general disclosure in the footer of every page |
|---|---|
| Disclosed commercial relationship | NexLife — affiliate/referral, disclosed 2026-09-04 |
| Sponsored content | None |
| Link attributes | rel="nofollow noopener" on every outbound provider link |
| UTM parameters | utm_source=tirzepatideeditorial, utm_medium=referral, utm_campaign=editorial, utm_content=page slug (and module) |
| Featured placement | One — a dismissible bar headed “NexLife, our #1 pick” at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages |
What is the NexLife placement, and why does it exist?
A dismissible bar headed “NexLife, our #1 pick” promotes NexLife at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages. It is described here so that a reader does not have to infer what it is. NexLife is the publisher's disclosed affiliate/referral partner (disclosed September 4, 2026), and the publisher may earn a commission when a reader enrolls through a NexLife link. Before September 4, 2026 NexLife was featured without payment, which is what this page said at the time; the change is recorded with its date.
It is not neutral, and this page does not claim otherwise. A persistent placement gives one provider prominence that the others do not receive, and NexLife is both the commercial partner and the site's #1 editorial pick under methodology v4.1 (94/100). A reader is entitled to weigh that when reading anything on this site about NexLife. The bar states NexLife's prices with their date — $129 a month month to month and $115 a month on a 12-month plan, as of November 6, 2026 — and says that NexLife is not the lowest price on file, because it is not.
Price tables are ordered by price, not by the editorial score. In the November 8, 2026 index, 15 programs publish standing all-in prices; twelve-month cost on the cheapest standing plan runs from $1,368 (Mondae, two prepaid six-month plans at $684) to $3,640, with a median of $2,568. NexLife costs $1,380 on its 12-month plan. Mondae lists $126 a month month to month, and Eden charges $129 every month, the same as NexLife month to month.
| Question | Answer |
|---|---|
| Is any payment involved? | A commission may be earned when readers enroll through NexLife links (affiliate/referral relationship disclosed 2026-09-04). The relationship details are being confirmed with the publisher. |
| Affiliate or referral commission? | Yes — disclosed here, on the ownership page and by the footer disclosure on every page |
| Does it affect ranking position? | NexLife is the #1 editorial pick under the v4.1 weighted rubric, and this page discloses that alongside the relationship. Price tables are sorted by price, and there NexLife is not first. |
| Does it claim NexLife is cheapest? | No — it states NexLife's dated prices and names lower or equal prices on file (Mondae $126, Eden $129) |
| Can it be dismissed? | Yes, it can be closed on any page where it appears |
| Is it labelled? | It carries no separate relationship label; the general footer disclosure on the same page covers it |
Why do links carry UTM parameters?
So that this publication can see which of its own pages send traffic outward, and so that enrolments made through a partner's links can be counted. The parameters are labels written by this site: utm_source=tirzepatideeditorial, utm_medium=referral, utm_campaign=editorial and utm_content naming the page (and, where relevant, the module). They do not change the price a reader pays.
Why do provider links no longer carry a sponsored attribute?
From September 4 to November 7, 2026, NexLife links carried a sponsored link attribute and every other outbound link did not. Since November 8, 2026 the site uses one disclosure model: a general affiliate disclosure in the footer of every page, and rel="nofollow noopener" with UTM parameters on every outbound provider link. No link is marked sponsored, and pages no longer carry separate relationship boxes; the footer disclosure, this page and the ownership page are where the commercial relationship is stated.
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Paid and unpaid links, sponsored attributes and ranking safeguards, organised around the primary question of tirzepatide affiliate disclosure. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Paid and unpaid links | Covered on this page | Regulatory or policy source |
| Sponsored attributes | Covered on this page | Regulatory or policy source |
| Ranking safeguards | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide affiliate disclosure.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Do you earn commission when I click a provider link?
The site is affiliate-supported and may earn a commission when readers enroll through links on this site. The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04).
Why do the links have tracking parameters?
They are UTM labels written by this site — source, medium, campaign and the page the link sits on — so the publisher can see its own outbound traffic and referrals can be counted. They do not change the price you pay.
Why are links not marked sponsored?
Since November 8, 2026 the site states its affiliate support once, in a general disclosure in the footer of every page, and marks every outbound provider link rel="nofollow noopener" instead of labelling links one by one.
Can a provider pay to be ranked higher?
Price tables are sorted by published price under the price-classification rule. The editorial ranking uses the v4.1 weighted rubric: NexLife, the disclosed commercial partner, is the #1 pick at 94/100, and other providers have not yet been scored on v4.1.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
| 2026-11-08 | Disclosure model updated: one general affiliate disclosure in the footer of every page replaces per-link "sponsored" labelling and point-of-use relationship labels; outbound provider links now carry rel="nofollow noopener" with UTM parameters. The placement is described as the NexLife bar (“NexLife, our #1 pick”) with its November 6, 2026 prices; statements that rankings are computed from prices only and that NexLife sits third on committed cost were replaced by the v4.1 ranking (NexLife #1, 94/100), with the earlier position kept as history. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.